

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-29. (canceled)

30 (currently amended) A pharmaceutical composition comprising a solid dispersion, wherein said solid dispersion includes a dispersion of amorphous ritonavir and a water soluble carrier, and wherein ritonavir in said pharmaceutical composition has markedly improved dissolution rate in 0.1 N HCl at 37°C as compared to neat ritonavir.

31. (previously presented) The pharmaceutical composition of claim 30, wherein said water soluble carrier is polyethylene glycol (PEG).

32. (previously presented) The pharmaceutical composition of claim 31, wherein said solid dispersion further comprises a dispersion of (2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methylbutanoyl]amino-1,6-diphenylhexane (ABT-378).

33. (previously presented) The pharmaceutical composition of claim 30, wherein said water soluble carrier is PEG 8000.

34. (previously presented) The pharmaceutical composition of claim 30, wherein said solid dispersion further comprises a dispersion of (2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methylbutanoyl]amino-1,6-diphenylhexane (ABT-378).

35. (currently amended) The pharmaceutical composition of claim 30, ~~further~~ comprising a hard gelatin capsule which encapsulates said solid dispersion.

36. (previously presented) The pharmaceutical composition of claim 30, wherein said solid dispersion is compressed into a tablet.

37-38. (canceled).

39. (new) The pharmaceutical composition of claim 30, further comprising a pharmaceutically-acceptable filler, diluent, lubricant or disintegrant.

40. (new) The pharmaceutical composition of claim 30, wherein said solid dispersion is ground and formulated into a delivery system.

41. (new) A method of treating an HIV infection comprising administering a pharmaceutical composition of claim 30 to a mammal in need of such treatment.

42. (new) A method of treating an HIV infection comprising administering a pharmaceutical composition of claim 34 to a mammal in need of such treatment.

43. (new) A pharmaceutical composition comprising ritonavir, wherein ritonavir in said composition is formulated as a solid dispersion of amorphous ritonavir in a matrix including a water soluble polymer.

44. (new) A pharmaceutical composition of claim 43, comprising a gelatin capsule which encapsulates said solid dispersion.

45. (new) A pharmaceutical composition of claim 43 which is a tablet comprising said solid dispersion.

46. (new) The pharmaceutical composition of claim 43, wherein said water soluble polymer is PEG.

47. (new) The pharmaceutical composition of claim 43, wherein said water soluble polymer is PEG 8000.

48. (new) The pharmaceutical composition of claim 43, wherein said solid dispersion further comprises 2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydropyrimid-2-onyl)-3-methylbutanoyl]amino-1,6-diphenylhexane (ABT-378).

49. (new) The pharmaceutical composition of claim 43, further comprising a pharmaceutically-acceptable filler, diluent, lubricant or disintegrant.

50. (new) The pharmaceutical composition of claim 43, wherein said solid dispersion is ground and formulated into a delivery system.

51. (new) A method of treating an HIV infection comprising administering a pharmaceutical composition of claim 43 to a mammal in need of such treatment.

52. (new) A method of treating an HIV infection comprising administering a pharmaceutical composition of claim 48 to a mammal in need of such treatment.